ClinicalTrials.gg

Program

Yellow Fever Vaccine

Also written as “Yellow fever vaccine (produced on serum-free Vero cells)”, “Yellow fever vaccine (live)” and “Yellow Fever vaccine”.

Its studies are mostly in Yellow Fever · Measles · Severe Dengue · Malaria · Streptococcal Infections, led by 4 companies.

Furthest: phase 3, since Sep 7, 201111 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi62 open or runningphase 3since Sep 7, 2011Sep 21, 2009none ahead
GlaxoSmithKline30 open or runningphase 3since Feb 23, 2016Dec 2, 2010none ahead
Novartis10 open or runningphase 3since Nov 3, 2011Nov 3, 2011none ahead
Sinopharm10 open or runningphase 3since Apr 30, 2024Apr 30, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 21, 2009First study: phase 2 study in Encephalitis, JapaneseNew to SanofiSanofi · NCT00982137 · 108 enrolled · Australia
  2. Dec 2, 2010GlaxoSmithKline’s first study: phase 2 study in Streptococcal InfectionsNew to GlaxoSmithKlineGlaxoSmithKline · NCT01262872 · 1,320 enrolled · Gambia
  3. Sep 7, 2011Phase 3 study in DengueSanofi · NCT01436396 · 792 enrolled · Colombia, Peru
  4. Nov 3, 2011Novartis’s first study: phase 3 study in Meningococcal InfectionsNew to NovartisNovartis · NCT01466387 · 552 enrolled · Czech Republic, Germany
  5. Feb 23, 2016Phase 3 study in MalariaGlaxoSmithKline · NCT02699099 · 699 enrolled · Ghana
  6. Jun 25, 2021Phase 2 study in Yellow FeverSanofi · NCT04942210 · 568 enrolled · United States
  7. Aug 17, 2021Phase 2 study in Yellow FeverSanofi · NCT05011123 · 690 enrolled · Finland, France, Germany and more
  8. Dec 19, 2023Phase 2 study in Salmonella InfectionsGlaxoSmithKline · NCT06213506 · 180 enrolled · Ghana
  9. Apr 30, 2024Sinopharm’s first study: phase 3 study in MeaslesNew to SinopharmSinopharm · NCT06399003 · 1,200 enrolled · Kenya
  10. May 23, 2025Phase 3 study in Yellow FeverSanofi · NCT07002060 · 640 enrolled · United States
  11. Oct 27, 2025Phase 3 study in Yellow FeverSanofi · NCT07222059 · 254 enrolled · Japan

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07222059Yellow Fever · Japan3CompletedSanofiDec 25, 2025254
NCT07002060Yellow Fever · United States3CompletedSanofiJan 20, 2026640
NCT06399003Measles · Kenya3CompletedSinopharmSep 15, 20241,200
NCT06213506Salmonella Infections · Ghana2CompletedGlaxoSmithKlineAug 6, 2026180
NCT05011123Yellow Fever · Finland, France, Germany and more2Active, not recruitingSanofiMay 23, 2022690
NCT04942210Yellow Fever · United States2Active, not recruitingSanofiJun 24, 2022568
NCT02699099Malaria · Ghana3CompletedGlaxoSmithKlineMar 14, 2018699
NCT01466387Meningococcal Infections · Czech Republic, Germany3CompletedNovartisApr 2012552
NCT01436396Dengue · Colombia, Peru3CompletedSanofiSep 2013792
NCT01262872Streptococcal Infections · Gambia2CompletedGlaxoSmithKlineMar 18, 20131,320
NCT00982137Encephalitis, Japanese · Australia2CompletedSanofiApr 2005108

How it is read

Names in the registry

  • “Yellow fever vaccine (produced on serum-free Vero cells)”, 2 entries
  • “Yellow fever vaccine (live)”, 2 entries
  • “Yellow Fever Vaccine”, 2 entries
  • “Yellow Fever vaccine”, 1 entry
  • “YF vaccine (live)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.